SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1/A
Document Type: S-1/A
Date Filed: 2026-03-18
Accession Number: 0001493152-26-010642
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226010642/forms-1a.htm

Chunk 53 of 85
Word Count: 1496
Character Count: 9656

Document Content:

● experience in corporate management, such as serving as an officer or former officer of a publicly-held company; ● experience as a board member or executive officer of another publicly-held company; ● strong finance experience; ● diversity of expertise and experience in substantive matters pertaining to our business relative to other board members; ● diversity of background and perspective including, without limitation, with respect to age, gender, race, place of residence and specialized experience; ● experience relevant to our business industry and with relevant social policy concerns; and ● relevant academic expertise or other proficiency in an area of our business operations. Role of Board in Risk Oversight Process Periodically, our board of directors assesses these roles and the board of directors leadership structure to ensure the interests of our company and our stockholders are best served. Our board of directors has determined that its current leadership structure is appropriate.

While
management is responsible for assessing and managing risks to our company, our board of directors is responsible for overseeing management’s
efforts to assess and manage risk. This oversight is conducted primarily by our full board of directors, which has responsibility for
general oversight of risks, and standing committees of our board of directors. Our board of directors satisfies this responsibility through
full reports by each committee chair regarding the committee’s considerations and actions, as well as through regular reports directly
from officers responsible for oversight of particular risks within our company. Our board of directors believes that full and open communications
between management and the board of directors are essential for effective risk management and oversight.

Compensation
Committee Interlocks and Insider Participation

None
of our executive officers serves, or in the past has served, as a member of the board of directors or compensation committee, or other
committee serving an equivalent function, of any entity that has one or more executive officers who serve as members of our board of
directors or our compensation committee. None of the members of our compensation committee is, or has ever been, an officer or employee
of our company.

Clawback
Policy

will adopt a compensation recovery policy that is compliant with Nasdaq listing rules as required by the Dodd-Frank Act.

Code
of Business Conduct and Ethics

or prior to the completion of this offering, we will adopt a written code of business conduct and ethics that applies to our employees,
officers and directors. A current copy of the code will be posted on the Corporate Governance section of our website, which will be located
at www.bioventrix.com. We intend to disclose future amendments to certain provisions of our code of business conduct and ethics,
or waivers of such provisions applicable to any principal executive officer, principal financial officer, principal accounting officer
or controller, or persons performing similar functions, and our directors, on our website identified above or in filings with the SEC.

Involvement
in Certain Legal Proceedings

Except
as otherwise disclosed below, to the best of our knowledge, none of our directors or executive officers has, during
the past ten years:

●	been
convicted in a criminal proceeding or been subject to a pending criminal proceeding (excluding traffic violations and other minor
offenses);

●	had
any bankruptcy petition filed by or against the business or property of the person, or of any partnership, corporation or business
association of which he was a general partner or executive officer, either at the time of the bankruptcy filing or within two years
prior to that time. Mr. Ravich served as a director of Orchids Paper Products Company from February 2013 to 2018, as well as chairman
of the governance committee and as a member of the audit committee. Orchids Paper Products Company filed for Chapter 11 bankruptcy
on April 1, 2019, in the U.S. Bankruptcy Court for the District of Delaware;

●	been
subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, by any court of competent jurisdiction
or federal or state authority, permanently or temporarily enjoining, barring, suspending or otherwise limiting, his involvement in
any type of business, securities, futures, commodities, investment, banking, savings and loan, or insurance activities, or to be
associated with persons engaged in any such activity;

●	been
found by a court of competent jurisdiction in a civil action or by the SEC or the Commodity Futures Trading Commission to have violated
a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated;

●	been
the subject of, or a party to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently
reversed, suspended or vacated (not including any settlement of a civil proceeding among private litigants), relating to an alleged
violation of any federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions
or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution,
civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order, or any law or regulation prohibiting
mail or wire fraud or fraud in connection with any business entity; or

●	been
the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization
(as defined in Section 3(a)(26) of the Exchange Act), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange
Act), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons
associated with a member.

From
time to time, we may be subject to various legal or administrative claims and proceedings arising in the ordinary course of business.
Litigation or any other legal or administrative proceeding, regardless of the outcome, is likely to result in substantial cost and diversion
of our company’s resources, including our company’s management’s time and attention.

EXECUTIVE
AND DIRECTOR COMPENSATION

The
following table sets forth the aggregate compensation paid to our named executive officers for the fiscal years ended December 31, 2025
and 2024. Individuals we refer to as our “named executive officers” include our Chief Executive Officer and our two other
most highly compensated executive officers who were serving as executive officers at the end of the fiscal year ended December 31, 2025
and whose total compensation for services rendered in all capacities exceeded $100,000 during the fiscal year ended December 31, 2025.

Summary
Compensation Table

Name and Principal Position Year Salary ($) Bonus ($) Stock Awards ($)(2) Option Awards ($)(2) Non-Equity Incentive Plan Compensation ($) Nonqualified Deferred Compensation Earnings ($) All Other Compensation ($) Total ($)

David Richmond, Chairman, Co-Chief Executive Officer and Chief Financial Officer 2025 $	300,000 - $	- $	8,900 - - $	36,176	(3) $	345,076

Steve Chartier, President, Co-Chief Executive Officer and Director 2025 $	375,000 $	50,000 $	- $	9,881 - - $	97,059	(4) $	531,940

Ori Ben-Yehuda, Chief Medical Officer 2025 - - $	- $	563 - - $	120,000	(5) $	120,563

(1)	This
amount reflects the pay out of unused vacation time for 2024.

(2)	Amounts
reflect the full grant-date fair value of restricted stock and stock option awards granted during the applicable fiscal year computed
in accordance with ASC Topic 718, rather than the amounts paid to or realized by the named executive officer. We provide information
regarding the assumptions used to calculate the value of all awards made to our named executive officers in Note 9 of the Consolidated
Financial Statements.

(3)	This
amount includes medical insurance of $32,552.

(4)	This
amount includes medical insurance of $63,569 and matching contributions in our 401(k) plan of $29,625.

(5)	Consulting
fees as our CMO is a consultant, paid monthly in arrears.

Employment
Arrangements with our Executive Officers and Directors

Current
Arrangements

Richmond is currently employed pursuant to an offer letter agreement with the Company that became effective January 15, 2025 (the “Richmond
Offer Letter”). Pursuant to the Richmond Offer Letter, Mr. Richmond serves as the Co-Chief Executive Officer of the Company, reporting
to the board of directors. The Richmond Offer Letter contains the following compensatory terms: (i) an annual base salary of $300,000,
(ii) eligibility to receive a discretionary bonus of up to 30% of his base salary, contingent upon the achievement of objectives mutually
agreed upon with the board of directors, and (iii) an option to purchase 191,000 shares of the Company’s common stock, which vests
as to 25% of the underlying shares on the first anniversary of the effective date of the award agreement, with the remaining 75% vesting
in equal monthly installments over the following 36 months, subject to Mr. Richmond’s continued employment. The options fully vest
upon a change in control of the Company. In the event the Company terminates Mr. Richmond’s employment without “cause”
or Mr. Richmond terminates his employment for “good reason” (each, as defined in the Richmond Offer Letter), Mr. Richmond
is entitled to receive severance equal to twelve months of his then-current base salary.